Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06710288
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dai, Guanghai
- Target Recruit Count
- 35
- Registration Number
- NCT06708858
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT06704191
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06694454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06662669
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06629597
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath